Paul Tudor Jones’s Novavax NVAX Stock Holding History

Paul Tudor Jones’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12M	Buy	+436,900	New	+$3.91M	0.01%	1418

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Paul Tudor Jones's NVAX Position: Q2 2026 in Review

Paul Tudor Jones reduced its Novavax (NVAX) stake by 2.6% in Q2 2026, selling an estimated $30.4K and leaving 125,468 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

Paul Tudor Jones first reported a position in NVAX in Q4 2013 and has held it in 21 quarters since. The position peaked at $3.48M in Q1 2022. 264 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Paul Tudor Jones held 125,468 shares of Novavax worth $1.18M as of Q2 2026.
Paul Tudor Jones sold 3,391 Novavax shares in Q2 2026, an estimated $30.4K.
Novavax made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2296 holding.
Paul Tudor Jones first reported a position in Novavax in Q4 2013 and has held it in 21 quarters since.
Paul Tudor Jones's Novavax position peaked at $3.48M in Q1 2022.
264 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.